Medical Devices: The Growing Opportunities for CMOs

In 2020, the global medical devices market is estimated to reach a net worth of approximately USD 430 billion. However, most developers lack adequate resources and the necessary expertise to manufacture medical devices and related components. Given the demand for medical devices, the opportunity for CMOs with expertise in medical devices is steadily rising. It

Neoantigen Targeted Therapies: Mapping the Future Growth Potential

The World Health Organization has estimated the number of new cancer cases, reported across the globe, to rise by 70% over the next 20 years. Conventional treatment options, such as chemotherapy, surgery and radiation therapy, continue to demonstrate limited efficacy in late-stage cancers. Recent developments in genomic analysis and advances in bioinformatics have enabled the

Biologics Fill / Finish Services: Current Landscape, Growth Opportunities and Future Market Outlook

According to a recent CDMO survey, about 54% respondents claimed to have collaborated with a contract service provider for clinical and commercial-scale product development projects. Specifically, fill / finish is the final step in the production process and is considered among the most crucial stages of drug product manufacturing. Biologic drug products require special procedures

Elastomeric Closures for Parenteral Containers: Current Market Landscape and Future Growth Opportunities

The use of elastomeric materials, along with various types of coatings (such as FluoroTec® and Teflon®) have emerged as a promising alternative to conventional, non-coated closures used for primary packaging containers, which were prone to leaching and shedding of particulate contaminants. The advantages of using elastomeric materials in manufacturing container closures are many, including low

Novel Immuno-Oncology Biomarker Testing: Focus on TMB, MSI / MMR and TILs

Advances in biotechnology have enabled the development of several high throughput tools, which have led to the establishment of better biomarkers based on genome / exome profiles. Novel biomarkers, such as tumour mutation burden (TMB), microsatellite instability (MSI) / mismatch repair (MMR) deficiency, tumour infiltrating lymphocytes (TILs) and certain others, are presently being investigated across

Changing Paradigms in Clinical Trials: Focus on Novel Trial Designs, Real World Evidence and Clinical Operations Management

Studies suggest that each prescription drug requires around 10 years and over USD 2.5 billion in working capital before it reaches the market. Further, it is estimated that, in the US, 40% of the pharma industry’s R&D budget is spent solely on conducting clinical trials. Estimates suggest that nearly 85% of clinical trials fail to

The Emergence of Encapsulated Cell Therapies and Affiliated Technologies

Extensive research on cell encapsulation strategies have enabled the development of a variety of technologies capable of confining therapeutic entities within biocompatible matrices / carriers. Since 2013, over 3,000 patents have been published related to the aforementioned type of therapy, indicating the rapid pace of R&D activities in this domain. I have highlighted below some